Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(33.3%)
Phase 3
1(33.3%)
Phase 1
1(33.3%)
3Total
N/A(1)
Phase 3(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07357675Phase 3Not Yet Recruiting

A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.

Role: collaborator

NCT04797260Phase 1Suspended

Phase I/II Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCID

Role: collaborator

NCT05157061Not ApplicableCompleted

GOS to Reduce Symptom Severity in IBS

Role: collaborator

All 3 trials loaded